Company Overview - Johnson & Johnson (JNJ) ended the latest trading session at $152.51, reflecting a -0.44% adjustment from the previous day's close, underperforming the S&P 500 which had a daily loss of 0.04% [1] - The stock has decreased by 1.42% over the past month, while the Medical sector gained 1.44% and the S&P 500 increased by 13.42% [1] Upcoming Financial Results - Analysts expect Johnson & Johnson to report earnings of $2.65 per share, indicating a year-over-year decline of 6.03% [2] - The consensus estimate for revenue is $22.77 billion, representing a 1.42% increase from the prior-year quarter [2] Annual Forecast - Zacks Consensus Estimates project earnings of $10.60 per share and revenue of $91.19 billion for the entire year, showing changes of +6.21% and +2.66% respectively compared to the previous year [3] - Recent revisions in analyst estimates are crucial as they reflect near-term business trends, with positive revisions indicating optimism about the company's profitability [3] Valuation Metrics - Johnson & Johnson is currently trading at a Forward P/E ratio of 14.45, which is a premium compared to the industry average Forward P/E of 13.21 [6] - The company has a PEG ratio of 2.32, while the Large Cap Pharmaceuticals industry has an average PEG ratio of 1.21 [6] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 40, placing it in the top 17% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Overview - Novo Nordisk (NVO) is a pharmaceutical company headquartered in Bagsvaerd, operating in the Medical sector [3] - The stock has experienced a price decline of 21.47% since the beginning of the year [3] Dividend Information - Novo Nordisk currently pays a dividend of $0.82 per share, resulting in a dividend yield of 2.43%, which is higher than the Large Cap Pharmaceuticals industry's yield of 2.37% and the S&P 500's yield of 1.6% [3] - The company's annualized dividend of $1.64 has increased by 59.8% compared to the previous year [4] - Over the last five years, Novo Nordisk has raised its dividend five times, achieving an average annual increase of 22.48% [4] - The current payout ratio is 22%, indicating that the company pays out 22% of its trailing 12-month earnings per share as dividends [4] Earnings Growth Expectations - For the fiscal year, Novo Nordisk anticipates solid earnings growth, with the Zacks Consensus Estimate for 2025 at $3.89 per share, reflecting an expected increase of 18.60% from the previous year [5] Investment Appeal - Novo Nordisk is considered a compelling investment opportunity due to its attractive dividend and strong Zacks Rank of 2 (Buy) [7]

Core Viewpoint - Novo Nordisk's stock has experienced a decline of -2.2% over the past month, underperforming the Zacks S&P 500 composite's -0.5% change and the Zacks Large Cap Pharmaceuticals industry's -2% loss, raising questions about its near-term performance [1] Earnings Estimate Revisions - The consensus earnings estimate for the current quarter is $0.91 per share, reflecting a year-over-year increase of +9.6%, with a recent change of +2.2% over the last 30 days [4] - For the current fiscal year, the consensus earnings estimate is $3.85, indicating a +17.4% change from the previous year, with a +1.3% change in the last 30 days [4] - The next fiscal year's consensus earnings estimate is $4.71, showing a +22.4% change from the prior year, with a +2.1% change over the past month [5] - Novo Nordisk holds a Zacks Rank 3 (Hold), influenced by recent changes in consensus estimates and other earnings-related factors [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $11.33 billion, indicating a year-over-year increase of +19.1% [10] - The sales estimates for the current and next fiscal years are $50.66 billion and $58.15 billion, reflecting changes of +20.3% and +14.8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Novo Nordisk achieved revenues of $12.26 billion, a year-over-year increase of +28.9%, and an EPS of $0.91 compared to $0.71 a year ago [11] - The reported revenues exceeded the Zacks Consensus Estimate of $11.34 billion by +8.11%, and the EPS surprise was +9.64% [11] - Over the last four quarters, Novo Nordisk surpassed consensus EPS estimates twice and revenue estimates twice [12] Valuation - Novo Nordisk is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers [16]

Company Overview - Roche Holding AG (RHHBY) currently holds a Momentum Style Score of B, indicating a favorable position in momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [4] Price Performance - Over the past week, RHHBY shares increased by 1.59%, while the Zacks Large Cap Pharmaceuticals industry rose by 3.52% [6] - In a longer time frame, RHHBY's monthly price change is 3.56%, outperforming the industry's 1.85% [6] - Over the last quarter, RHHBY shares have increased by 0.59%, and over the past year, they have gained 37.04% [7] - In comparison, the S&P 500 has moved -7.43% over the last quarter and 12.15% over the past year [7] Trading Volume - RHHBY's average 20-day trading volume is 2,416,640 shares, which serves as a price-to-volume baseline for assessing momentum [8] Earnings Outlook - In the past two months, two earnings estimates for RHHBY have moved higher, with no downward revisions, boosting the consensus estimate from $2.83 to $2.93 [10] - For the next fiscal year, three estimates have increased, with no downward revisions during the same period [10] Conclusion - Considering the positive price performance, trading volume, and favorable earnings outlook, RHHBY is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.11%. A quarter ago, it was expected that this drugmaker would post earnings of $5.03 per share when it actually produced earnings of $5.32, delivering a surprise of 5.77%.Over the last four quarters, the company has su ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Roche Holding AG (RHHBY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Roche Holding AG is one of 1000 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different g ...

Core Viewpoint - Pfizer reported quarterly earnings of $0.92 per share, exceeding the Zacks Consensus Estimate of $0.64 per share, and showing an increase from $0.82 per share a year ago, representing an earnings surprise of 43.75% [1][2] Financial Performance - Pfizer's revenues for the quarter ended March 2025 were $13.72 billion, which missed the Zacks Consensus Estimate by 0.88% and decreased from $14.88 billion year-over-year [2] - Over the last four quarters, Pfizer has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Pfizer shares have declined approximately 13.1% since the beginning of the year, compared to a 6% decline in the S&P 500 [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.58 on revenues of $13.74 billion, and for the current fiscal year, it is $2.99 on revenues of $63.48 billion [7] - The estimate revisions trend for Pfizer is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Large Cap Pharmaceuticals industry, to which Pfizer belongs, is currently ranked in the top 14% of over 250 Zacks industries, suggesting a positive outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - AbbVie reported quarterly earnings of $2.46 per share, exceeding the Zacks Consensus Estimate of $2.39 per share, and showing an increase from $2.31 per share a year ago, representing an earnings surprise of 2.93% [1] - The company achieved revenues of $13.34 billion for the quarter, surpassing the Zacks Consensus Estimate by 3.39% and increasing from $12.31 billion year-over-year [2] - AbbVie has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of AbbVie’s stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.09 on revenues of $14.8 billion, and for the current fiscal year, it is $12.20 on revenues of $59.58 billion [7] Industry Context - The Large Cap Pharmaceuticals industry, to which AbbVie belongs, is currently ranked in the top 21% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of AbbVie’s stock may also be influenced by the overall industry outlook and trends [8] Competitor Insights - Eli Lilly, a competitor in the same industry, is expected to report quarterly earnings of $3.52 per share, reflecting a year-over-year increase of 36.4%, with revenues anticipated to be $12.62 billion, up 43.9% from the previous year [9][10]

Merck (MRK) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.07 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 3.26%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $1.69 per share when it actually produced earnings of $1.72, delivering a surprise of 1.78%. Over the last four quarters, the com ...

The most recent trading session ended with Eli Lilly (LLY) standing at $827.54, reflecting a +1.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 2.51%. Elsewhere, the Dow gained 2.66%, while the tech-heavy Nasdaq added 2.71%. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a cl ...